Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib

被引：0
作者：
Mauro, Francesca R. [1 ]
Foa, Robin [1 ]
机构：
[1] Sapienza Univ, Dept Cellular Biotechnol & Haematol, Rome, Italy
来源：
LANCET ONCOLOGY | 2018年 / 19卷 / 01期
关键词：
RESISTANCE; OUTCOMES;
D O I：
10.1016/S1470-2045(17)30910-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 8
页数：3
相关论文
共 10 条
  • [1] Targeted therapies for CLL: Practical issues with the changing treatment paradigm
    Jain, Nitin
    O'Brien, Susan
    [J]. BLOOD REVIEWS, 2016, 30 (03) : 233 - 244
  • [2] Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
    Jain, Preetesh
    Keating, Michael
    Wierda, William
    Estrov, Zeev
    Ferrajoli, Alessandra
    Jain, Nitin
    George, Binsah
    James, Danelle
    Kantarjian, Hagop
    Burger, Jan
    O'Brien, Susan
    [J]. BLOOD, 2015, 125 (13) : 2062 - 2067
  • [3] PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment
    Jones, D.
    Woyach, J. A.
    Zhao, W.
    Caruthers, S.
    Tu, H.
    Coleman, J.
    Byrd, J. C.
    Johnson, A. J.
    Lozanski, G.
    [J]. LEUKEMIA, 2017, 31 (07) : 1645 - 1647
  • [4] Jones JA, 2017, LANCET ONCOL
  • [5] Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
    Mato, A. R.
    Hill, B. T.
    Lamanna, N.
    Barr, P. M.
    Ujjani, C. S.
    Brander, D. M.
    Howlett, C.
    Skarbnik, A. P.
    Cheson, B. D.
    Zent, C. S.
    Pu, J. J.
    Kiselev, P.
    Foon, K.
    Lenhart, J.
    Bachow, S. Henick
    Winter, A. M.
    Cruz, A. -L.
    Claxton, D. F.
    Goy, A.
    Daniel, C.
    Isaac, K.
    Kennard, K. H.
    Timlin, C.
    Fanning, M.
    Gashonia, L.
    Yacur, M.
    Svoboda, J.
    Schuster, S. J.
    Nabhan, C.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (05) : 1050 - 1056
  • [6] Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
    Mato, Anthony R.
    Nabhan, Chadi
    Barr, Paul M.
    Ujjani, Chaitra S.
    Hill, Brian T.
    Lamanna, Nicole
    Skarbnik, Alan P.
    Howlett, Christina
    Pu, Jeffrey J.
    Sehgal, Alison R.
    Strelec, Lauren E.
    Vandegrift, Alexandra
    Fitzpatrick, Danielle M.
    Zent, Clive S.
    Feldman, Tatyana
    Goy, Andre
    Claxton, David F.
    Bachow, Spencer Henick
    Kaur, Gurbakhash
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Porter, David
    Landsburg, Daniel J.
    Schuster, Stephen J.
    Cheson, Bruce D.
    Kiselev, Pavel
    Evens, Andrew M.
    [J]. BLOOD, 2016, 128 (18) : 2199 - 2205
  • [7] Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    Roberts, Andrew W.
    Davids, Matthew S.
    Pagel, John M.
    Kahl, Brad S.
    Puvvada, Soham D.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary Ann
    Brown, Jennifer R.
    Gressick, Lori
    Wong, Shekman
    Dunbar, Martin
    Zhu, Ming
    Desai, Monali B.
    Cerri, Elisa
    Enschede, Sari Heitner
    Humerickhouse, Rod A.
    Wierda, William G.
    Seymour, John F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) : 311 - 322
  • [8] Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
    Seymour, John F.
    Ma, Shuo
    Brander, Danielle M.
    Choi, Michael Y.
    Barrientos, Jacqueline
    Davids, Matthew S.
    Anderson, Mary Ann
    Beaven, Anne W.
    Rosen, Steven T.
    Tam, Constantine S.
    Prine, Betty
    Agarwal, Suresh K.
    Munasinghe, Wijith
    Zhu, Ming
    Lash, L. Leanne
    Desai, Monali
    Cerri, Elisa
    Verdugo, Maria
    Kim, Su Young
    Humerickhouse, Rod A.
    Gordon, Gary B.
    Kipps, Thomas J.
    Roberts, Andrew W.
    [J]. LANCET ONCOLOGY, 2017, 18 (02) : 230 - 240
  • [9] Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Schetelig, Johannes
    Coutre, Steven
    Seymour, John F.
    Munir, Talha
    Puvvada, Soham D.
    Wendtner, Clemens-Martin
    Roberts, Andrew W.
    Jurczak, Wojciech
    Mulligan, Stephen P.
    Boettcher, Sebastian
    Mobasher, Mehrdad
    Zhu, Ming
    Desai, Monali
    Chyla, Brenda
    Verdugo, Maria
    Enschede, Sari Heitner
    Cerri, Elisa
    Humerickhouse, Rod
    Gordon, Gary
    Hallek, Michael
    Wierda, William G.
    [J]. LANCET ONCOLOGY, 2016, 17 (06) : 768 - 778
  • [10] BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Ruppert, Amy S.
    Guinn, Daphne
    Lehman, Amy
    Blachly, James S.
    Lozanski, Arletta
    Heerema, Nyla A.
    Zhao, Weiqiang
    Coleman, Joshua
    Jones, Daniel
    Abruzzo, Lynne
    Gordon, Amber
    Mantel, Rose
    Smith, Lisa L.
    McWhorter, Samantha
    Davis, Melanie
    Doong, Tzyy-Jye
    Ny, Fan
    Lucas, Margaret
    Chase, Weihong
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Maddocks, Kami
    Rogers, Kerry
    Jaglowski, Samantha
    Andritsos, Leslie A.
    Awan, Farrukh T.
    Blum, Kristie A.
    Grever, Michael R.
    Lozanski, Gerard
    Johnson, Amy J.
    Byrd, John C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (13) : 1437 - +
1